Serum aminotransferase activity and mortality risk in a United States community

Hoon Lee Tae, W. Ray Kim, Joanne T. Benson, Terry M Therneau, L. Joseph Melton

Research output: Contribution to journalArticle

99 Citations (Scopus)

Abstract

Serum aminotransferase [such as aspartate aminotransferase (AST) and alanine aminotransferase (ALT)] is commonly used as an indicator of liver disease. The aim of the study was to determine the degree to which aminotransferase results are associated with increased mortality at the population level. All adult residents of Olmsted County, Minnesota, who had a health care encounter at Mayo Clinic, Rochester, in 1995 were identified and their AST or ALT results extracted from a laboratory database. These subjects were followed forward from January 1995 to April 2006 and their survival determined. To exclude patients with abnormal results because of a terminal illness, deaths within the first 2 years were excluded. The main outcome measure was survival. Standardized mortality ratios (SMRs) were calculated, based on Minnesota White death rates. During 1995, AST was measured at least once in 18,401 community residents, of whom 2,350 (13%) had results greater than the upper limit of normal (ULN). Of 6,823 subjects who had their ALT measured, 911 (13%) had results higher than ULN. Abnormal AST was associated with a significantly increased SMR (1.32 for 1-2X ULN and 1.78 for >2X ULN). SMR was also higher for abnormal ALT (SMR = 1.21 for 1-2X ULN and 1.51 for > 2X ULN). In contrast, normal AST or ALT was associated with a risk of death lower than expected (SMR 0.95 for AST, 0.61 for ALT). Conclusion: Serum levels of AST and ALT obtained in a routine medical care setting are associated with future mortality in community residents.

Original languageEnglish (US)
Pages (from-to)880-887
Number of pages8
JournalHepatology
Volume47
Issue number3
DOIs
StatePublished - Mar 2008

Fingerprint

Transaminases
Aspartate Aminotransferases
Alanine Transaminase
Mortality
Serum
Survival
Liver Diseases
Outcome Assessment (Health Care)
Databases
Delivery of Health Care
Population

ASJC Scopus subject areas

  • Hepatology
  • Medicine(all)

Cite this

Serum aminotransferase activity and mortality risk in a United States community. / Tae, Hoon Lee; Kim, W. Ray; Benson, Joanne T.; Therneau, Terry M; Melton, L. Joseph.

In: Hepatology, Vol. 47, No. 3, 03.2008, p. 880-887.

Research output: Contribution to journalArticle

Tae, Hoon Lee ; Kim, W. Ray ; Benson, Joanne T. ; Therneau, Terry M ; Melton, L. Joseph. / Serum aminotransferase activity and mortality risk in a United States community. In: Hepatology. 2008 ; Vol. 47, No. 3. pp. 880-887.
@article{bf32aedf98674d5c86b88c741c5ad1b9,
title = "Serum aminotransferase activity and mortality risk in a United States community",
abstract = "Serum aminotransferase [such as aspartate aminotransferase (AST) and alanine aminotransferase (ALT)] is commonly used as an indicator of liver disease. The aim of the study was to determine the degree to which aminotransferase results are associated with increased mortality at the population level. All adult residents of Olmsted County, Minnesota, who had a health care encounter at Mayo Clinic, Rochester, in 1995 were identified and their AST or ALT results extracted from a laboratory database. These subjects were followed forward from January 1995 to April 2006 and their survival determined. To exclude patients with abnormal results because of a terminal illness, deaths within the first 2 years were excluded. The main outcome measure was survival. Standardized mortality ratios (SMRs) were calculated, based on Minnesota White death rates. During 1995, AST was measured at least once in 18,401 community residents, of whom 2,350 (13{\%}) had results greater than the upper limit of normal (ULN). Of 6,823 subjects who had their ALT measured, 911 (13{\%}) had results higher than ULN. Abnormal AST was associated with a significantly increased SMR (1.32 for 1-2X ULN and 1.78 for >2X ULN). SMR was also higher for abnormal ALT (SMR = 1.21 for 1-2X ULN and 1.51 for > 2X ULN). In contrast, normal AST or ALT was associated with a risk of death lower than expected (SMR 0.95 for AST, 0.61 for ALT). Conclusion: Serum levels of AST and ALT obtained in a routine medical care setting are associated with future mortality in community residents.",
author = "Tae, {Hoon Lee} and Kim, {W. Ray} and Benson, {Joanne T.} and Therneau, {Terry M} and Melton, {L. Joseph}",
year = "2008",
month = "3",
doi = "10.1002/hep.22090",
language = "English (US)",
volume = "47",
pages = "880--887",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - Serum aminotransferase activity and mortality risk in a United States community

AU - Tae, Hoon Lee

AU - Kim, W. Ray

AU - Benson, Joanne T.

AU - Therneau, Terry M

AU - Melton, L. Joseph

PY - 2008/3

Y1 - 2008/3

N2 - Serum aminotransferase [such as aspartate aminotransferase (AST) and alanine aminotransferase (ALT)] is commonly used as an indicator of liver disease. The aim of the study was to determine the degree to which aminotransferase results are associated with increased mortality at the population level. All adult residents of Olmsted County, Minnesota, who had a health care encounter at Mayo Clinic, Rochester, in 1995 were identified and their AST or ALT results extracted from a laboratory database. These subjects were followed forward from January 1995 to April 2006 and their survival determined. To exclude patients with abnormal results because of a terminal illness, deaths within the first 2 years were excluded. The main outcome measure was survival. Standardized mortality ratios (SMRs) were calculated, based on Minnesota White death rates. During 1995, AST was measured at least once in 18,401 community residents, of whom 2,350 (13%) had results greater than the upper limit of normal (ULN). Of 6,823 subjects who had their ALT measured, 911 (13%) had results higher than ULN. Abnormal AST was associated with a significantly increased SMR (1.32 for 1-2X ULN and 1.78 for >2X ULN). SMR was also higher for abnormal ALT (SMR = 1.21 for 1-2X ULN and 1.51 for > 2X ULN). In contrast, normal AST or ALT was associated with a risk of death lower than expected (SMR 0.95 for AST, 0.61 for ALT). Conclusion: Serum levels of AST and ALT obtained in a routine medical care setting are associated with future mortality in community residents.

AB - Serum aminotransferase [such as aspartate aminotransferase (AST) and alanine aminotransferase (ALT)] is commonly used as an indicator of liver disease. The aim of the study was to determine the degree to which aminotransferase results are associated with increased mortality at the population level. All adult residents of Olmsted County, Minnesota, who had a health care encounter at Mayo Clinic, Rochester, in 1995 were identified and their AST or ALT results extracted from a laboratory database. These subjects were followed forward from January 1995 to April 2006 and their survival determined. To exclude patients with abnormal results because of a terminal illness, deaths within the first 2 years were excluded. The main outcome measure was survival. Standardized mortality ratios (SMRs) were calculated, based on Minnesota White death rates. During 1995, AST was measured at least once in 18,401 community residents, of whom 2,350 (13%) had results greater than the upper limit of normal (ULN). Of 6,823 subjects who had their ALT measured, 911 (13%) had results higher than ULN. Abnormal AST was associated with a significantly increased SMR (1.32 for 1-2X ULN and 1.78 for >2X ULN). SMR was also higher for abnormal ALT (SMR = 1.21 for 1-2X ULN and 1.51 for > 2X ULN). In contrast, normal AST or ALT was associated with a risk of death lower than expected (SMR 0.95 for AST, 0.61 for ALT). Conclusion: Serum levels of AST and ALT obtained in a routine medical care setting are associated with future mortality in community residents.

UR - http://www.scopus.com/inward/record.url?scp=40949103928&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40949103928&partnerID=8YFLogxK

U2 - 10.1002/hep.22090

DO - 10.1002/hep.22090

M3 - Article

VL - 47

SP - 880

EP - 887

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 3

ER -